• SIBO Symposium 2018, All Presentations

    Original Date: June 9-10, 2018

    Small intestine bacterial overgrowth (SIBO) is a chronic bacterial colonization of the small intestine. These bacteria normally live in the gastrointestinal tract, however, in SIBO they have overgrown in a location not meant for so many bacteria. The bacteria interfere with our normal digestion and absorption of food and are associated with damage to the lining or membrane of the small intestine. These mechanisms in turn lead to myriad other disorders—gastrointestinal, systemic, and neurological.

    The 5th Annual SIBO Symposium features the nation’s leading experts on the topic to present an evidence-based educational program on managing small intestine bacterial overgrowth. For more information, visit www.sibosymposium.com

    Presentations include:
    • Exploring the Intersection between Eating Disorders and SIBO/IBS
    • Evolving Story of Autoimmunity in the Development of SIBO
    • Ehlers-Danlos Syndrome, Joint Hypermobility, POTS
    • Mast Cell Activation Syndrome
    • The Importance of Gas Type in SIBO
    • The Thyroid and SIBO
    • Pelvic Inflammatory Processes Part I: Endometriosis, Adenomyosis and Dysmenorrhea
    • Expert Panels
    • Pelvic Inflammatory Processes Part 2: PID, TOA and Ectopic Pregnancy – An Integrative Exploration
    • The Parasite/SIBO connection
    • Pre-Diabetes/Diabetes as Underlying Causes

    12.00 CEUs (including 3.5 pharmacy and 8.5 general) for NDs approved by OBNM
  • Exploring the Intersection between Eating disorders and SIBO/IBS

    Presenters: Megan Taylor, ND & Sara Hopkins, ND, LAc
    Original Date: June 9, 2018

    Disordered eating behaviors can have a profound impact on digestive physiology, resulting in changes to motility, anatomy, digestive secretions, immunologic status, and microbial balance. These changes often lead individuals with eating disorders to develop any number of functional gastrointestinal disorders (FGID), with some studies estimating a 98% prevalence of FGID in patients with an eating disorder (Boyd, et al. 2005). And to make matter more complex, the symptoms of the eating disorder itself can often be indistinguishable from the symptoms of these gastrointestinal disorders, making it difficult for clinicians to identify appropriate treatment strategies. This overlap can present challenges in the setting of a functional GI practice, and poses some difficult questions. How do we appropriately screen for and recognize patients who have eating disorders? How do we ensure that our interventions do not cause harm to these patients? Do we consider dietary modification or other cornerstones of digestive health treatments in this patient population? This presentation will explore these questions, as well as provide useful tools for clinical evaluation, management, and appropriate referrals for patients with disordered eating behavior and diagnosable eating disorders.


    1.5 general CEUs approved by OBNM
  • Evolving Story of Autoimmunity in the Development of SIBO

    Presenter: Mark Pimentel, MD, FRCP(C)
    Original Date: June 9, 2018

    It is becoming increasingly clear that SIBO is in some cases due to previous exposure to gastroenteritis. Through a series of interesting studies, it is now understood that this singe food poisoning event can lead to long term changes in the microbiome. The most important of these is the development of antibodies to vinculin. In this presentation, we will update the audience on the latest developments on this topic and how the future is shaping up to treat SIBO and IBS as an autoimmune condition.

    1.0 general CEUs approved by OBNM
  • Expert Panel Saturday : Moderated by Lisa Shaver, ND

    Presenters: Megan Taylor, ND, Sara Hopkins, ND, LAc & Mark Pimentel, M.D.
    Original Date: June 9, 2018

    Presenters respond to questions from the audience regarding content covered by Drs. Taylor, Hopkins and Pimentel. A mixture of data, clinical experiences and outcomes and case examples are covered.

    0.5 general CEUs approved by OBNM
  • Ehlers-Danlos Syndrome, Joint Hypermobility, POTS

    Presenter: Alena Guggenheim, ND
    Original Date: Ma 19, 2018

    Ehlers-Danlos and generalized joint hypermobility syndromes are common genetic connective tissues disorders that can present in a heterogenous pattern. This talk will discuss the subtypes of EDS, common comorbidities, red flag symptoms that indicate possible CNS involvement and a treatment approach to improving outcomes. We will also over a common co-morbidity, postural orthostatic tachycardia syndrome that can impact gastrointestinal motility and predispose patients to developing small intestinal bacterial overgrowth. We will discuss lifestyle and pharmaceutical approaches to treatment for POTS. The following medications will be discussed: Florinef, midodrine, beta-blockers, IV saline, low dose naltrexone, mestinon, and Corlanor.


    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • Mast Cell Activation Syndrome

    Presenter: Leonard B. Weinstock, MD
    Original Date: June 9, 2018

    Small intestinal bacterial overgrowth (SIBO) is a syndrome in that it has multiple causes. Motility disorders are most often the underlying factors to predispose for the development of SIBO. Postural orthostatic tachycardia syndrome (POTS) leads to an imbalanced autonomic nervous system because excessive sympathetic activity overrides vagal tone. Peristalsis is reduced and SIBO may be promoted. Mast cell activation syndrome (MCAS) is a leading factor in 33% of POTS. It is also conceivable that MCAS could directly impact motility via one of 200 mediators that may reduce neuromuscular activity.
    It is important to recognize POTS which has a prevalence of 500,000-1,000,000 in the US. Understanding this disease and the more prevalent MCAS (1 – 17% of the population) is critical to help many patients who otherwise suffer for decades without a diagnosis and/or effective therapy.
    Specific pharmaceutical medications to be discussed in both the overview and outline: rifaximin and naltrexone..


    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • The Importance of Gas Type in SIBO

    Presenter: Mark Pimentel, M.D., FRCP(C)
    Original Date: June 9, 2018

    In the last decade, the understanding of clinical breath testing in the evaluation of SIBO has evolved. We have come to know that methane on breath testing is highly associated with constipation and requires a different approach to treatment. Hydrogen on the other hand is not related to any specific symptom. The missing gas has been hydrogen sulfide and this gas is of great importance to the symptom diarrhea. Not having this gas in the breath test profile leaves a missing piece of the puzzle out. In this presentation we will examine the interaction of all three gases and the importance they play in the evolving microbiome story of SIBO. Rifaximin will be discussed which is FDA approved, neomycin a drug not yet approved for SIBO and SYN-010 which is not yet approved by FDA for methane.

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • Expert Panel Saturday 2: Moderated by Lisa Shaver, ND

    Presenters: Alena Guggenheim, ND, Leonard B. Weinstock, MD & Mark Pimentel, MD
    Original Date: June 9, 2018

    Presenters respond to questions from the audience regarding content covered by Drs. Guggenheim, Weinstock and Pimentel. A mixture of data, clinical experiences and outcomes and case examples are covered.

    0.5 general CEUs approved by OBNM
  • SIBO and the Thyroid: A Significant Relationship

    Presenter: Gary Weiner, N.D., L.Ac.
    Original Date: June 10, 2018

    In continuing the discussion of the principle of treating underlying causes of SIBO rather than simply focusing therapy on reduction of bacterial overgrowth, we cannot overlook the thyroid gland’s role in motility. Evidence has emerged for thyroid disorders as one of SIBO’s etiologies. This presentation explores SIBO’s intersections with dysthyroidsm, and points to implications in developing effective treatment plans and strategies for prevention of recurrence.
    The presentation will include a brief overview of thyroid prescribing, both clinically and sub-clinically, including use of Levothyroxin, Tri-iodothyronine, dessicated Thyroid USP, and compound prescribing.

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • Pelvic Inflammatory Processes Part I: Endometriosis, Adenomyosis and Dysmenorrhea

    Presenter: Lara Williams, MD, FACOG and Stefani Hayes ND, LAc
    Original Date: June 10, 2018

    The conditions of endometriosis, adenomyosis, and dysmenorrhea and their treatments have many consequences on the body. We will discuss how traditional management not only affects the pelvic inflammatory processes themselves but how it also impacts other inflammatory processes in the body, including SIBO. We will also show how pelvic inflammatory processes can have similar symptoms to SIBO.
    Pharmaceuticals to be discussed include: OCPs, Lupron, NSAIDS (including ponstel), Mirena IUD, Progestins (including norethindrone and Depo Provera), and Narcotics (including oxycodone and hydrocodone)

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • Pelvic Inflammatory Processes Part 2: PID, TOA and Ectopic Pregnancy – An Integrative Exploration

    Presenters: Lara Williams, MD, FACOG and Stefani Hayes ND, LAc
    Original Date: June 10, 2018

    Pelvic inflammatory disease (PID), Tubo-Ovarian Abcesses (TOA) and ectopic pregnancy can have numerous negative effects on the body. We will discuss how traditional management not only affects these pelvic inflammatory processes but also how it impacts other inflammatory processes, including SIBO. We will expound on current theories regarding the possible etiologies of numerous pelvic inflammatory processes and how this impacts our understanding of other inflammatory processes, including SIBO.
    Pharmaceuticals to be discussed include: antibiotics such as azithromycin, Doxycycline, Ceftriaxone, Gentamicin and Flagyl as well as methotrexate

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • The Parasite/SIBO Connection

    Presenter: Ilana Gurevich ND, LAc
    Original Date: June 10, 2018

    This is a discussion of the connection between how both SIBO and parasitic infections affect the Microbiome and how one is often misdiagnosed as another. This will be a deeper look on how we currently understand how parasitic infections change the microbiome presentation and how patients will often suffer from and be diagnosed with one but the underlying cause is the other one.
    Alinia is briefly discussed as a use for treatment of parasitic infections.

    1.0 general CEUs approved by OBNM
  • Diabetic Enteropathy and SIBO

    Presenter: Steven Sandberg-Lewis ND, DHANP
    Original Date: June 10, 2018

    This presentation will explain how metabolic syndrome, prediabetes and frank diabetes become key underlying causes for SIBO and other GI disorders. The influences of lipopolysaccharides from overgrown flora, autonomic neuropathy, hepatic insulin resistance, effects of hyperglycemia and the hypothalamic-pituitary-adrenal axis on upper GI transit. SS-L will use example cases to show his approach to diabetes treatment and management.
    Pharmaceuticals to be discussed include: Metformin, berberine, allicin, oregano, ginger and neem will be discussed with regards to diabetes, insulin resistance and SIBO.

    1.0 CEUs (including 0.5 general and 0.5 pharmacy) approved by OBNM
  • Expert Panel Sunday: Moderated by Lisa Shaver, ND

    Presenters: Gary Weiner, ND, Lara Williams, MD, FACOG, Dr. Stefani Hayes ND, LAc, Ilana Gurevich ND, LAc, & Steven Sandberg-Lewis, ND
    Original Date: June 10. 2018

    Presenters respond to questions from the audience regarding content from Sunday covered by the day's presenters. A mixture of data, clinical experiences and outcomes and case examples are covered.

    0.5 general CEUs approved by OBNM

Privacy Policy